Physician profile
Diana Rivera
NPI 1568034783
$4,209.52
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $398 · 2022: $2,211 · 2023: $1,461 · 2024: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.05 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $657.50 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $458.88 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $368.78 | 2022 | |
| Preventric Diagnostics, INC. | $342.07 | 2022 | |
| Pfizer INC. | $275.55 | 2021-2024 | |
| Lilly USA, LLC | $253.78 | 2021-2023 | Jardiance, Emgality, Mounjaro |
| Exact Sciences Corporation | $171.75 | 2023 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $158.82 | 2022-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $152.01 | 2022-2023 | Breztri |
| Amgen INC. | $143.40 | 2021-2023 | Otezla, Repatha |
| Astellas Pharma US INC | $122.79 | 2022-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $114.17 | 2021-2024 | Trintellix |
| Abbott Laboratories | $114.11 | 2022-2023 | Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $109.91 | 2022 | |
| Mylan Specialty L.P. | $106.82 | 2021-2023 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $96.08 | 2021-2023 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.19 | 2022-2023 | Jardiance |
| Organon LLC | $71.24 | 2023 | Nexplanon |
| Eisai INC. | $59.41 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.36 | 2022-2023 | Verquvo, Belsomra |
| Otsuka America Pharmaceutical, INC. | $55.69 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $46.13 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $44.45 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $43.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.06 | 2022-2023 | |
| Xeris Pharmaceuticals, INC. | $26.36 | 2023 | Gvoke Hypopen |
| Biohaven Pharmaceuticals, INC. | $18.45 | 2021 | |
| Sobi, INC | $12.61 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.